Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R S Fujinami

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Brain Pathology (Zurich, Switzerland)|July 23, 1999
Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNAI Tsunoda, N D Tolley, D J Theil, et al.
Journal of Virology|July 20, 2001
Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff BI Tsunoda, Y Wada, J E Libbey, et al.
Journal of Neuroimmunology|July 17, 1999
Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitisJ W Rose, C T Welsh, K E Hill, et al.
Journal of Neuroimmunology|April 1, 1998
Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infectionJ W Rose, K E Hill, Y Wada, et al.
The Journal of General Virology|October 27, 2012
Theiler's murine encephalomyelitis virus contrasts with encephalomyocarditis and foot-and-mouth disease viruses in its functional utilization of the StopGo non-standard translation mechanismG Loughran, J E Libbey, S Uddowla, et al.
Beneficial Microbes|October 13, 2020
Modulation of experimental autoimmune encephalomyelitis through colonisation of the gut with <i>Escherichia coli</i>J E Libbey, J M S Sanchez, B A Fleming, et al.
Beneficial Microbes|January 31, 2018
Variations in diet cause alterations in microbiota and metabolites that follow changes in disease severity in a multiple sclerosis modelJ E Libbey, J M Sanchez, D J Doty, et al.
Vaccine|March 6, 1999
Lipopeptide particles as the immunologically active component of CTL inducing vaccinesI Tsunoda, A Sette, R S Fujinami, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Brain Pathology (Zurich, Switzerland)|July 23, 1999
Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNAI Tsunoda, N D Tolley, D J Theil, et al.
Journal of Virology|July 20, 2001
Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff BI Tsunoda, Y Wada, J E Libbey, et al.
Journal of Neuroimmunology|July 17, 1999
Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitisJ W Rose, C T Welsh, K E Hill, et al.
Journal of Neuroimmunology|April 1, 1998
Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infectionJ W Rose, K E Hill, Y Wada, et al.
The Journal of General Virology|October 27, 2012
Theiler's murine encephalomyelitis virus contrasts with encephalomyocarditis and foot-and-mouth disease viruses in its functional utilization of the StopGo non-standard translation mechanismG Loughran, J E Libbey, S Uddowla, et al.
Beneficial Microbes|October 13, 2020
Modulation of experimental autoimmune encephalomyelitis through colonisation of the gut with <i>Escherichia coli</i>J E Libbey, J M S Sanchez, B A Fleming, et al.
Beneficial Microbes|January 31, 2018
Variations in diet cause alterations in microbiota and metabolites that follow changes in disease severity in a multiple sclerosis modelJ E Libbey, J M Sanchez, D J Doty, et al.
Vaccine|March 6, 1999
Lipopeptide particles as the immunologically active component of CTL inducing vaccinesI Tsunoda, A Sette, R S Fujinami, et al.
Pageof 7